Alnylam Pharmaceuticals, Inc. (ALNY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)

ALNY 456.04

+1.4%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (121)	9/26/2007 3:56:01 PM
From: tuck	Read Replies (1) of 166

Glad I waited a bit, but shorted via naked calls this afternoon. So far, so good. Zacks, not best known for their biotech research, agrees with our basic thesis: >>Too Early for ALNY Profits Wednesday September 26, 11:29 am ET By Zacks Equity Research A Hold recommendation has recently been issued to pharmaceutical company Alnylam Pharmaceuticals, Inc. (NasdaqGM: ALNY - News) by Zacks senior pharmaceutical industry analysts Grant Zeng, CFA and Varun Parwal. Here's what their latest update had to say: Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. The company possesses a deep, but very early-stage therapeutic pipeline. Merck's (NYSE: MRK - News) billion-dollar acquisition of Sirna and the recent multi-million-dollar Alnylam Roche(Other OTC: RHHBY.PK - News) deal provide an insight into the revenue potential the RNAi technology holds. We would like to remind investors that with just one candidate in clinical stage development, we are hesitant to project any product related revenues for Alnylam before 2010. We do not believe investors should pay for therapeutic candidates in early stages of clinical development. There are far too many development risks before we can assume Alnylam can commercialize anything using the technology. Valuation is difficult. We value Alnylam using relative valuation metrics. We come up with a $36 price target with a market cap of $1.4 billion.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next